Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136,035 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study.
Chen J, Wu S, Hu C, Yang Y, Rajan N, Chen Y, Yang C, Li J, Chen W. Chen J, et al. Among authors: chen w, chen y. Clinicoecon Outcomes Res. 2016 Apr 26;8:97-111. doi: 10.2147/CEOR.S98548. eCollection 2016. Clinicoecon Outcomes Res. 2016. PMID: 27217784 Free PMC article.
Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study.
Wang Y, Chen J, Wu S, Hu C, Li X, Wang Y, Yang Y, Rajan N, Chen Y, Chen Y, Luo Z, Chen W. Wang Y, et al. Among authors: chen j, chen w, chen y. BMC Cancer. 2014 Dec 12;14:940. doi: 10.1186/1471-2407-14-940. BMC Cancer. 2014. PMID: 25495098 Free PMC article.
Tumor response and clinical toxicity associated with second-line chemotherapy regimens for advanced non-squamous non-small cell lung cancer: A retrospective cohort study.
Hu C, Wang Y, Chen J, Wu S, Li X, Wang Y, Yang Y, Rajan N, Papadimitropoulos M, Xiao Q, Zhan H, Chen W. Hu C, et al. Among authors: chen j, chen w. Thorac Cancer. 2014 Sep;5(5):365-76. doi: 10.1111/1759-7714.12102. Epub 2014 Aug 25. Thorac Cancer. 2014. PMID: 26767027 Free PMC article.
Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study.
Li X, Wang Y, Wang Y, Chen J, Wu S, Hu C, Yang Y, Rajan N, Papadimitropoulos M, Chen Y, Peng T, Chen W. Li X, et al. Among authors: chen j, chen w, chen y. Drugs Real World Outcomes. 2015 Mar;2(1):87-97. doi: 10.1007/s40801-015-0017-6. Drugs Real World Outcomes. 2015. PMID: 27747618 Free PMC article.
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Huang J, et al. Among authors: chen z, chen j, chen y. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416073 Clinical Trial.
Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506).
Song Y, Zhou Q, Zhang X, Chen GY, Zhong DS, Yu Z, Yu P, Zhang YP, Chen JH, Hu Y, Feng GS, Song X, Shi Q, Yang LL, Yao LD, Zhan LJ, Yang F, Wu YL. Song Y, et al. Lung Cancer. 2018 Sep;123:7-13. doi: 10.1016/j.lungcan.2018.06.008. Epub 2018 Jun 18. Lung Cancer. 2018. PMID: 30089597
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J. Zhou C, et al. Among authors: chen j, chen x. Lancet Oncol. 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038432 Clinical Trial.
136,035 results
You have reached the last available page of results. Please see the User Guide for more information.